The Insider and shareholder of ANSYS, Inc. (ANSS), James Cashman, Sold 40,254 Shares; Shorts at Diplomat Pharmacy (DPLO) Raised By 17.29%

ANSYS, Inc. (NASDAQ:ANSS) Logo

Diplomat Pharmacy Inc (NYSE:DPLO) had an increase of 17.29% in short interest. DPLO’s SI was 7.40 million shares in May as released by FINRA. Its up 17.29% from 6.31M shares previously. With 1.03 million avg volume, 7 days are for Diplomat Pharmacy Inc (NYSE:DPLO)’s short sellers to cover DPLO’s short positions. The SI to Diplomat Pharmacy Inc’s float is 14.9%. The stock decreased 0.41% or $0.1 during the last trading session, reaching $24.15. About 571,088 shares traded. Diplomat Pharmacy, Inc. (NYSE:DPLO) has risen 34.38% since May 25, 2017 and is uptrending. It has outperformed by 22.83% the S&P500.

Investors sentiment decreased to 0.89 in 2017 Q4. Its down 0.08, from 0.97 in 2017Q3. It is negative, as 26 investors sold ANSYS, Inc. shares while 182 reduced holdings. 73 funds opened positions while 113 raised stakes. 77.82 million shares or 1.78% less from 79.23 million shares in 2017Q3 were reported. Qs Invsts Ltd Com has invested 0% of its portfolio in ANSYS, Inc. (NASDAQ:ANSS). 4,399 are held by Raymond James Finance Service. Advisory Service Networks Ltd Liability, a Georgia-based fund reported 5,027 shares. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 141,236 shares. State Of Tennessee Treasury Department holds 0.03% of its portfolio in ANSYS, Inc. (NASDAQ:ANSS) for 40,525 shares. Sit Invest Associates owns 45,245 shares. Janney Montgomery Scott Ltd Liability Corp has 0.02% invested in ANSYS, Inc. (NASDAQ:ANSS) for 14,520 shares. Tompkins Fincl holds 0.01% or 374 shares. Paradigm Asset Mgmt Limited Liability Corporation holds 150 shares. Art Advsr Ltd Co invested in 40,500 shares or 0.26% of the stock. Moreover, American Century has 0% invested in ANSYS, Inc. (NASDAQ:ANSS). 3 are owned by Hanson Mcclain. Gotham Asset Mgmt Limited Liability invested 0.16% in ANSYS, Inc. (NASDAQ:ANSS). Legal And General Gp Public Lc reported 480,539 shares. Sumitomo Life holds 10,480 shares or 0.19% of its portfolio.

Company insider, James Cashman, shareholder of Ansys Inc unloaded a total of 40,254 shares of the firm, based on a market stock price of $163.8 for every share. James Cashman currently has ownership of 425,006 shares or 0.51% of Ansys Inc’s market cap.

More recent ANSYS, Inc. (NASDAQ:ANSS) news were published by: Seekingalpha.com which released: “ANSYS, Inc. 2018 Q1 – Results – Earnings Call Slides” on May 03, 2018. Also Prnewswire.com published the news titled: “ANSYS Awarded 2018 Achievement In Customer Excellence” on May 22, 2018. Streetinsider.com‘s news article titled: “ANSYS (ANSS) Acquires OPTIS” with publication date: May 02, 2018 was also an interesting one.

Among 16 analysts covering Ansys Inc. (NASDAQ:ANSS), 4 have Buy rating, 2 Sell and 10 Hold. Therefore 25% are positive. Ansys Inc. has $19000 highest and $86 lowest target. $133.73’s average target is -18.07% below currents $163.22 stock price. Ansys Inc. had 38 analyst reports since August 6, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, May 3 by MUFG Securities Americas Inc. The firm has “Buy” rating by Berenberg given on Tuesday, January 30. The rating was downgraded by Wedbush on Friday, May 6 to “Neutral”. The stock of ANSYS, Inc. (NASDAQ:ANSS) earned “Hold” rating by Needham on Friday, September 15. The stock of ANSYS, Inc. (NASDAQ:ANSS) earned “Hold” rating by Evercore on Wednesday, August 2. The firm has “Overweight” rating by Mitsubishi UFJ given on Tuesday, February 9. The stock of ANSYS, Inc. (NASDAQ:ANSS) has “Buy” rating given on Thursday, February 22 by Robert W. Baird. The stock has “Underweight” rating by Barclays Capital on Friday, September 15. Barclays Capital downgraded the shares of ANSS in report on Friday, January 6 to “Underweight” rating. Robert W. Baird maintained ANSYS, Inc. (NASDAQ:ANSS) rating on Friday, September 29. Robert W. Baird has “Buy” rating and $130.0 target.

The stock decreased 0.57% or $0.94 during the last trading session, reaching $163.22. About 483,057 shares traded or 8.43% up from the average. ANSYS, Inc. (NASDAQ:ANSS) has risen 48.65% since May 25, 2017 and is uptrending. It has outperformed by 37.10% the S&P500.

Since February 1, 2018, it had 0 buys, and 7 selling transactions for $9.19 million activity. SHIELDS MARIA T had sold 25,000 shares worth $4.06M. $4.04 million worth of ANSYS, Inc. (NASDAQ:ANSS) shares were sold by MORLEY BRADFORD C. Shares for $136,196 were sold by CASHMAN JAMES E III. $156,610 worth of ANSYS, Inc. (NASDAQ:ANSS) was sold by HINDSBO MARK on Thursday, March 8. The insider MAHONEY RICHARD S. sold 2,039 shares worth $330,338. Another trade for 1,222 shares valued at $199,149 was made by ZACK MATTHEW C. on Saturday, April 28.

ANSYS, Inc. develops and markets engineering simulation software and services used by engineers, designers, researchers, and students in the aerospace and defense, automotive, industrial equipment, electronics, biomedical, energy, materials and chemical processing, and semiconductors industries and academia worldwide. The company has market cap of $13.71 billion. The firm offers ANSYS Workbench, a framework upon which the companyÂ’s engineering simulation technologies are built; ANSYS Engineering Knowledge Manager, a solution for simulation process and data management challenges; and high-performance computing product suite that delivers cross-physics parallel processing capabilities for simulation software. It has a 50.55 P/E ratio. It also offers geometry handling solutions; meshing technology that transforms a physical model into a mathematical model; structural analysis product suite for product design and optimization; explicit dynamics product suite that simulates events; and composite analysis and optimization technology, as well as customization services.

Analysts await ANSYS, Inc. (NASDAQ:ANSS) to report earnings on August, 1. They expect $0.92 EPS, up 3.37% or $0.03 from last year’s $0.89 per share. ANSS’s profit will be $77.29M for 44.35 P/E if the $0.92 EPS becomes a reality. After $1.09 actual EPS reported by ANSYS, Inc. for the previous quarter, Wall Street now forecasts -15.60% negative EPS growth.

Since March 9, 2018, it had 0 insider buys, and 1 sale for $44.40 million activity. 2.15M shares were sold by Hagerman Philip R, worth $44.40M.

Investors sentiment increased to 1.89 in Q4 2017. Its up 0.45, from 1.44 in 2017Q3. It is positive, as 17 investors sold Diplomat Pharmacy, Inc. shares while 40 reduced holdings. 45 funds opened positions while 63 raised stakes. 47.12 million shares or 4.65% less from 49.42 million shares in 2017Q3 were reported. Fred Alger Incorporated reported 0.06% in Diplomat Pharmacy, Inc. (NYSE:DPLO). North Carolina-based Sterling Capital Lc has invested 0.02% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Northwestern Mutual Wealth Management holds 165 shares. Captrust Financial Advisors reported 0% of its portfolio in Diplomat Pharmacy, Inc. (NYSE:DPLO). Morgan Stanley holds 376,166 shares. Old National Natl Bank In reported 18,742 shares. Alphamark Advsr Limited Liability Corporation holds 41,046 shares or 0.32% of its portfolio. Moreover, Ny State Common Retirement Fund has 0% invested in Diplomat Pharmacy, Inc. (NYSE:DPLO) for 132,358 shares. Alliancebernstein L P invested in 180,900 shares or 0% of the stock. Trexquant L P holds 0.04% or 16,661 shares in its portfolio. Sivik Global Limited Com owns 0.74% invested in Diplomat Pharmacy, Inc. (NYSE:DPLO) for 100,000 shares. Tennessee-based State Of Tennessee Treasury Department has invested 0% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Zurcher Kantonalbank (Zurich Cantonalbank) invested 0% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Citigroup Inc holds 0% or 72,168 shares in its portfolio. Financial Bank reported 20,815 shares stake.

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company has market cap of $1.79 billion. The firm stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It has a 105.92 P/E ratio. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

More recent Diplomat Pharmacy, Inc. (NYSE:DPLO) news were published by: Seekingalpha.com which released: “Diplomat Pharmacy 2018 Q1 – Results – Earnings Call Slides” on May 08, 2018. Also Streetinsider.com published the news titled: “Diplomat Pharmacy (DPLO) Appoints Brian Griffin as CEO and Chairman” on May 10, 2018. Streetinsider.com‘s news article titled: “Diplomat Pharmacy (DPLO) Misses Q1 EPS by 2c, Beats on Revenues” with publication date: May 07, 2018 was also an interesting one.

Among 17 analysts covering Diplomat Pharmacy (NYSE:DPLO), 8 have Buy rating, 0 Sell and 9 Hold. Therefore 47% are positive. Diplomat Pharmacy had 47 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Hold” rating by Credit Suisse given on Thursday, January 25. The firm earned “Neutral” rating on Wednesday, October 14 by Bank of America. The stock of Diplomat Pharmacy, Inc. (NYSE:DPLO) has “Hold” rating given on Wednesday, January 24 by Mizuho. Morgan Stanley downgraded Diplomat Pharmacy, Inc. (NYSE:DPLO) rating on Friday, October 2. Morgan Stanley has “Equal-Weight” rating and $31 target. Leerink Swann maintained Diplomat Pharmacy, Inc. (NYSE:DPLO) on Tuesday, August 4 with “Outperform” rating. The firm has “Buy” rating given on Thursday, May 10 by J.P. Morgan. The stock has “Neutral” rating by Bank of America on Tuesday, June 7. On Thursday, November 3 the stock rating was maintained by Mizuho with “Neutral”. Needham maintained the shares of DPLO in report on Wednesday, November 8 with “Buy” rating. As per Monday, December 11, the company rating was upgraded by Leerink Swann.

Diplomat Pharmacy, Inc. (NYSE:DPLO) Institutional Positions Chart